There were 841 press releases posted in the last 24 hours and 442,547 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image